GlassScriptPhysician profile
Sorot Phisitkul
NPI 1457576704
$9,786.23
in general payments reported to CMS, 2019-2025
34 companies · $1,861 in 2025
The $1,861 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,093 · 2020: $482 · 2021: $1,141 · 2022: $1,812 · 2023: $1,441 · 2024: $1,957 · 2025: $1,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,144 · Consulting Fee: $90.00 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,144.26 |
| Consulting Fee | $90.00 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,929.56 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $1,058.31 | 2021-2025 | |
| Amgen INC. | $983.09 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $896.90 | 2019-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $574.65 | 2021-2023 | Benlysta |
| Horizon Therapeutics Plc | $527.15 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $450.01 | 2022-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $421.19 | 2019-2023 | Ultomiris |
| Vifor Pharma, INC. | $347.83 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.74 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $229.54 | 2019-2025 | Velphoro, Velphoro, Optiflux |
| Daiichi Sankyo INC. | $227.14 | 2019-2024 | Injectafer |
| Akebia Therapeutics INC | $209.35 | 2019-2024 | Vafseo, Auryxia |
| Novo Nordisk INC | $178.30 | 2023-2025 | Ozempic |
| Ardelyx, INC. | $169.90 | 2024-2025 | Ibsrela |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $153.30 | 2023-2024 | |
| Scpharmaceuticals INC. | $151.22 | 2025 | |
| Ani Pharmaceuticals, INC. | $136.33 | 2023-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $134.63 | 2022-2025 | Gattex |
| Aimmune Therapeutics, INC. | $108.59 | 2024 | |
| Mallinckrodt Hospital Products INC. | $91.44 | 2020-2025 | Terlivaz |
| Opko Pharmaceuticals, LLC | $90.91 | 2024-2025 | Rayaldee |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.35 | 2019 | |
| Cormedix INC. | $63.41 | 2024-2025 | Defencath, Defencath |
| Aurinia Pharma U.S., INC. | $55.90 | 2021-2023 | Lupkynis |
| Alnylam Pharmaceuticals INC. | $54.08 | 2021-2024 | Givlaari |
| Ultragenyx Pharmaceutical INC. | $44.84 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $41.89 | 2023-2025 | |
| Nevro Corp. | $28.79 | 2024 | Senza |
| Lilly USA, LLC | $25.34 | 2024 | Jardiance |
| Allergan, INC. | $19.05 | 2019 | |
| Arbor Pharmaceuticals, INC. | $18.59 | 2021 | |
| Baxter Healthcare | $18.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sorot Phisitkul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.